VXRT · Vaxart, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about our ability to continue as a going concern for a period of one year from the date of the issuance of these consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-16 | Watson W. Mark |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. |
Stock Options (right to buy)
|
78,700 |
| 2026-07-16 | BREITMEYER JAMES B |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. |
Stock Options (right to buy)
|
16,610 |
| 2026-07-16 | Finney Kevin |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. |
Common Stock
|
39,400 |
| 2026-07-16 | BREITMEYER JAMES B |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. |
Common Stock
|
8,315 |
| 2026-07-16 | Watson W. Mark |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. |
Common Stock
|
39,400 |
| 2026-07-16 | HERON ELAINE J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. |
Common Stock
|
39,400 |
| 2026-07-16 | Finney Kevin |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. |
Stock Options (right to buy)
|
78,700 |
| 2026-07-16 | HERON ELAINE J |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. |
Stock Options (right to buy)
|
78,700 |
| 2026-07-16 | Wheadon David E. |
Director |
Award↑
Filing footnotes — Stock Options (right to buy) (Direct)
The shares subject to this option shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary of the date of the grant. |
Stock Options (right to buy)
|
78,700 |
| 2026-07-16 | Wheadon David E. |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2027 annual meeting of stockholders of the Issuer and July 16, 2027, the first anniversary date of the grant. |
Common Stock
|
39,400 |
| 2026-05-22 | Watson W. Mark |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2026-05-19 | Grasman Jeroen Nicolaas |
Chief Financial Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of May 19, 2026. |
Common Stock
|
31,395 |
| 2026-04-23 | BREITMEYER JAMES B |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-04-23 | BREITMEYER JAMES B |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board of Directors (the "Board"). |
Common Stock
|
78,800 |
| 2026-04-23 | BREITMEYER JAMES B |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to this option shall vest in equal installments on each of the first three anniversaries of the grant date, subject to the reporting person's continuing service on the Board. |
Stock Option (right to buy)
|
157,400 |
| 2026-03-28 | Tucker Sean |
SVP, Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. |
Common Stock
|
3,924 |
| 2026-03-28 | Cummings James F. |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 28, 2026. This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
3,292 |
| 2026-03-24 | Cummings James F. |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
30,551 |
| 2026-03-24 | Lo Steven |
Director, President, Chief Exec Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. |
Common Stock
|
126,028 |
| 2026-03-24 | Berg Edward B |
SVP, General Counsel |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. This amount includes 70,781 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
36,418 |
| 2026-03-24 | Tucker Sean |
SVP, Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 24, 2026. |
Common Stock
|
36,418 |
| 2026-03-18 | Cummings James F. |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
6,772 |
| 2026-03-18 | Berg Edward B |
SVP, General Counsel |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. This amount includes 70,781 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
8,072 |
| 2026-03-18 | Tucker Sean |
SVP, Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. |
Common Stock
|
8,072 |
| 2026-03-18 | Lo Steven |
Director, President, Chief Exec Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of March 18, 2026. |
Common Stock
|
22,425 |
| 2026-03-16 | Tucker Sean |
SVP, Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. |
Common Stock
|
200,000 |
| 2026-03-16 | Cummings James F. |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. |
Stock Option (right to buy)
|
455,000 |
| 2026-03-16 | Tucker Sean |
SVP, Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. |
Stock Option (right to buy)
|
410,000 |
| 2026-03-16 | Cummings James F. |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. |
Common Stock
|
227,000 |
| 2026-03-16 | Lo Steven |
Director, President, Chief Exec Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. |
Common Stock
|
846,500 |
| 2026-03-16 | Grasman Jeroen Nicolaas |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. |
Stock Option (right to buy)
|
455,000 |
| 2026-03-16 | Berg Edward B |
SVP, General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. |
Common Stock
|
115,000 |
| 2026-03-16 | Grasman Jeroen Nicolaas |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units. 25% of the shares underlying the award shall vest on each anniversary of the vesting commencement date of March 16, 2026, so that the restricted stock units would be fully vested on the fourth anniversary of the vesting commencement date. |
Common Stock
|
227,000 |
| 2026-03-16 | Berg Edward B |
SVP, General Counsel |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. |
Stock Option (right to buy)
|
225,000 |
| 2026-03-16 | Lo Steven |
Director, President, Chief Exec Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The shares subject to this stock option shall vest as to 25% of the shares underlying the grant on March 16, 2027, the first anniversary of the date that vesting commenced, and thereafter in 36 equal monthly installments such that the stock option shall be fully vested on March 16, 2030. |
Stock Option (right to buy)
|
1,543,000 |
| 2026-02-02 | Berg Edward B |
SVP, General Counsel |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. This amount includes 70,781 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
9,265 |
| 2026-02-02 | Cummings James F. |
Chief Medical Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. This amount includes 75,618 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
7,965 |
| 2026-02-02 | Tucker Sean |
SVP, Chief Scientific Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of February 2, 2026. |
Common Stock
|
9,265 |
| 2025-12-04 | Lo Steven |
Director, President, Chief Exec Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Grant of shares upon vesting of restricted stock units, which fully vested on December 4, 2025. This amount includes 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan. |
Common Stock
|
151,351 |
| 2025-12-04 | Lo Steven |
Director, President, Chief Exec Officer |
Tax↓
Filing footnotes — Common Stock (Direct)
Represents shares that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs vested as of December 4, 2025. |
Common Stock
|
54,153 |
| 2025-11-17 | Watson W. Mark |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
This Form 4 is being filed late due to delays in receiving EDGAR access codes. |
Common Stock
|
15,000 |
| 2025-11-17 | HERON ELAINE J |
Director |
Buy↑
|
Common Stock
|
16,783 |
| 2025-11-17 | HERON ELAINE J |
Director |
Buy↑
|
Common Stock
|
23,217 |
| 2025-11-17 | Watson W. Mark |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
This Form 4 is being filed late due to delays in receiving EDGAR access codes. |
Common Stock
|
5,000 |
| 2025-08-15 | Finney Kevin |
Director |
Buy↑
|
Common Stock
|
50,000 |
| 2025-08-15 | Finney Kevin |
Director |
Buy↑
|
Common Stock
|
50,000 |
| 2025-07-30 | Finney Kevin |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
This transaction is being reported late due to an administrative oversight. |
Common Stock
|
25,874 |
| 2025-07-29 | Watson W. Mark |
Director |
Buy↑
|
Common Stock
|
10,000 |
| 2025-07-28 | Finney Kevin |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
This transaction is being reported late due to an administrative oversight. |
Common Stock
|
20,000 |
| 2025-07-25 | Finney Kevin |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
This transaction is being reported late due to an administrative oversight. |
Common Stock
|
20,000 |